Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

Shares of Monte Rosa TherapeuticsGLUE surged to a nearly four-year high Tuesday after the biotech company said all four ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

Oct. 21, 2025 – A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to unprecedented results of a drug treatment trial in men whose ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...

So far, “the only established risk factors for prostate cancer are advancing age, African ancestry, and a family history of ...

Adams said that after asking President Trump to give him access to the drug Pluvicto, his sessions with the drug have been ...